Our results indicate that proteasome inhibitors are potent antagonists of the c-MYC regulon, highlight the transcriptional dynamics between gene activators and repressors in multiple myeloma, and open potential avenues for personalized treatment options involving epigenetic modifiers. This evidence concerns the gene MYC and plasma cell myeloma.